TapewireFind a company

person · Reporting owner

Catinazzo Thomas

Disclosed activity across 1 company

Tapewire entity
22284
SEC CIK
0001818261

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Relay Therapeutics, Inc.RLAY · Entity 4044Chief Financial OfficerOctober 06, 2026October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Relay Therapeutics, Inc.

Report date October 06, 2026 · Filed October 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,134 Last balance in matching sequence After 2026-10-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-10-06 · Sale · Disposed 17,511 · Balance 105,340

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 6,538 shares underlying restricted stock units.

Row 2 · 2026-10-06 · Sale · Disposed 206 · Balance 105,134

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 6,538 shares underlying restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 6,538 shares underlying restricted stock units.

F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 06, 2026 Filed Oct 8, 2026 21:29 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 206 $19.26 $3,967.56
Disclosure

SEC source: 0001193125-26-418094 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,134

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 6,538 shares underlying restricted stock units.

Read SEC document
October 06, 2026 Filed Oct 8, 2026 21:29 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,511 $18.58 $325,354.38
Disclosure

SEC source: 0001193125-26-418094 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,340

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 6,538 shares underlying restricted stock units.

Read SEC document
September 08, 2026 Filed Sep 9, 2026 20:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $18.94 $335,559.98
Disclosure

SEC source: 0001193125-26-386464 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,851

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.34 to $19.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 6,538 shares underlying restricted stock units.

Read SEC document
August 14, 2026 Filed Aug 18, 2026 20:16 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $19.74 $349,733.58
Disclosure

SEC source: 0001193125-26-355493 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,568

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 6,538 shares underlying restricted stock units.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 20:13 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,459 $18.61 $27,151.99
Disclosure

SEC source: 0001193125-26-326144 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,285

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 6,538 shares underlying RSUs.

Read SEC document
July 06, 2026 Filed Jul 8, 2026 21:07 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $18.69 $331,130.73
Disclosure

SEC source: 0001193125-26-298679 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,744

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $18.39 to $19.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 51,560 $0.00 Strike: $4.45 $0.00
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 10

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 223,440

Underlying: Common Stock · 51,560 shares

Expires 2035-01-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F7 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 61,563 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 9

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 61,563 shares

Expires 2030-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F6 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 56,323 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · derivative · entry 8

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,323 shares

Expires 2029-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F5 · derivative.exercise_date: The shares underlying this stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of April 23, 2019.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 51,560 $16.97 $874,973.20
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 7

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,461

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 51,560 $4.45 $229,442.00
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 6

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 229,021

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 61,563 $16.97 $1,044,724.11
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 5

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,461

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 61,563 $5.22 $321,358.86
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 4

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 56,323 $16.97 $955,801.31
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 3

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,461

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4 · price: This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 56,323 $5.04 $283,867.92
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
June 22, 2026 Filed Jun 24, 2026 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $17.01 $301,366.17
Disclosure

SEC source: 0001193125-26-281061 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,461

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.38 to $17.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
May 14, 2026 Filed May 14, 2026 22:44 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $12.86 $227,840.62
Disclosure

SEC source: 0001193125-26-224545 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,178

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $12.67 to $13.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 9,807 shares underlying restricted stock units.

Read SEC document
April 28, 2026 Filed Apr 30, 2026 20:22 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 972 $14.79 $14,375.88
Disclosure

SEC source: 0001193125-26-197419 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,895

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,268 shares of restricted stock units ("RSUs") on April 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 9,807 shares underlying RSUs.

Read SEC document
April 09, 2026 Filed Apr 10, 2026 00:55 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionStock Option (Right to Buy) · Derivative 1,800 $0.00 Strike: $5.22 $0.00
Disclosure

SEC source: 0001193125-26-150044 · ownership.xml · derivative · entry 4

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,563

Underlying: Common Stock · 1,800 shares

Expires 2030-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F4 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, vested in sixteen (16) equal quarterly installments following March 11, 2021.

Read SEC document
April 09, 2026 Filed Apr 10, 2026 00:55 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,800 $15.00 $27,000.00
Disclosure

SEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 3

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,867

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F3 · balance_after: Includes 13,075 shares underlying restricted stock units.

Read SEC document
April 09, 2026 Filed Apr 10, 2026 00:55 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 Exercise / conversionCommon Stock 1,800 $5.22 $9,396.00
Disclosure

SEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 215,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F3 · balance_after: Includes 13,075 shares underlying restricted stock units.

Read SEC document
April 07, 2026 Filed Apr 10, 2026 00:55 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $13.01 $230,498.17
Disclosure

SEC source: 0001193125-26-150044 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,867

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $12.42 to $13.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 13,075 shares underlying restricted stock units.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 20:30 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 17,717 $10.06 $178,233.02
Disclosure

SEC source: 0001193125-26-102270 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 231,584

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

F2 · price: This transaction was executed in multiple trades at prices ranging from $9.77 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3 · balance_after: Includes 13,075 shares underlying restricted stock units.

Read SEC document
January 28, 2026 Filed Jan 29, 2026 21:20 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,695 $8.45 $14,322.75
Disclosure

SEC source: 0001193125-26-029403 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,301

F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of RSUs on January 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F4 · balance_after: Includes 13,075 shares underlying RSUs.

Read SEC document
January 27, 2026 Filed Jan 29, 2026 21:20 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 13,820 $7.62 $105,308.40
Disclosure

SEC source: 0001193125-26-029403 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,996

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,394 shares of restricted stock units ("RSUs") on January 26, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 18,799 shares underlying RSUs.

Read SEC document
January 13, 2026 Filed Jan 15, 2026 21:12 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantStock Option (Right to Buy) · Derivative 400,000 $0.00 Strike: $7.94 $0.00
Disclosure

SEC source: 0001193125-26-014106 · ownership.xml · derivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2036-01-12

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date.

Read SEC document
October 28, 2025 Filed Oct 30, 2025 20:15 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 21,664 $7.29 $157,930.56
Disclosure

SEC source: 0001193125-25-258574 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,631

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 48,115 shares of restricted stock units ("RSUs") on October 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 110,008 shares underlying RSUs.

Read SEC document
July 29, 2025 Filed Jul 30, 2025 20:54 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 18,380 $3.68 $67,638.40
Disclosure

SEC source: 0000950170-25-100366 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,295

F3 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,393 shares of RSUs on July 28, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F4 · balance_after: Includes 158,123 shares underlying RSUs.

Read SEC document
July 28, 2025 Filed Jul 30, 2025 20:54 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,701 $3.74 $6,361.74
Disclosure

SEC source: 0000950170-25-100366 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,675

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on July 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 200,516 shares underlying RSUs.

Read SEC document
April 30, 2025 Filed May 1, 2025 00:24 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 12,943 $3.00 $38,829.00
Disclosure

SEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 4

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 355,376

F4 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 42,392 shares of RSUs on April 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F5 · balance_after: Includes 206,240 shares underlying RSUs.

Read SEC document
April 29, 2025 Filed May 1, 2025 00:24 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 3,558 $3.23 $11,492.34
Disclosure

SEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 3

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 368,319

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 248,632 shares underlying RSUs.

Read SEC document
April 28, 2025 Filed May 1, 2025 00:24 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 981 $3.17 $3,109.77
Disclosure

SEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 371,877

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 248,632 shares underlying RSUs.

Read SEC document
April 28, 2025 Filed May 1, 2025 00:24 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,709 $3.17 $5,417.53
Disclosure

SEC source: 0000950170-25-061366 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 372,858

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,722 shares of restricted stock units ("RSUs") on April 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 248,632 shares underlying RSUs.

Read SEC document
March 27, 2025 Filed Mar 31, 2025 20:13 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 4,566 $2.84 $12,967.44
Disclosure

SEC source: 0000950170-25-047725 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 374,567

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 254,354 shares underlying RSUs.

Read SEC document
March 27, 2025 Filed Mar 31, 2025 20:13 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 298 $2.84 $846.32
Disclosure

SEC source: 0000950170-25-047725 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,133

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 254,354 shares underlying RSUs.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 02:10 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 20,791 $4.42 $91,896.22
Disclosure

SEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 5

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,431

F6 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 69,570 shares of RSUs on January 29, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F7 · balance_after: Includes 255,346 shares underlying RSUs.

Read SEC document
January 29, 2025 Filed Jan 31, 2025 02:10 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 2,109 $4.55 $9,595.95
Disclosure

SEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 4

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 400,222

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F5 · balance_after: Includes 324,916 shares underlying RSUs.

Read SEC document
January 28, 2025 Filed Jan 31, 2025 02:10 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantCommon Stock 139,141 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 3

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 402,331

F4 · shares: Represents RSUs granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.

F5 · balance_after: Includes 324,916 shares underlying RSUs.

Read SEC document
January 28, 2025 Filed Jan 31, 2025 02:10 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 2,283 $4.63 $10,570.29
Disclosure

SEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 263,190

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 185,775 shares underlying RSUs.

Read SEC document
January 28, 2025 Filed Jan 31, 2025 02:10 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 33,753 $4.63 $156,276.39
Disclosure

SEC source: 0000950170-25-011327 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 265,473

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 105,723 shares of restricted stock units ("RSUs") on January 27, 2025. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 185,775 shares underlying RSUs.

Read SEC document
January 10, 2025 Filed Jan 15, 2025 02:00 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 GrantStock Option (Right to Buy) · Derivative 275,000 $0.00 Strike: $4.45 $0.00
Disclosure

SEC source: 0000950170-25-005564 · ownership.xml · derivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2035-01-09

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 10, 2025, subject to the reporting person's continued service with the Issuer through each vesting date.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 21:05 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 4,566 $4.42 $20,181.72
Disclosure

SEC source: 0000950170-24-141597 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 299,226

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $4.37 to $4.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 291,498 shares underlying RSUs.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 21:05 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 299 $4.38 $1,309.62
Disclosure

SEC source: 0000950170-24-141597 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,792

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on December 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 291,498 shares underlying RSUs.

Read SEC document
October 29, 2024 Filed Oct 30, 2024 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 2,300 $5.95 $13,685.00
Disclosure

SEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 3

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 304,091

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 292,490 shares underlying RSUs.

Read SEC document
October 28, 2024 Filed Oct 30, 2024 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 5,105 $6.06 $30,936.30
Disclosure

SEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 306,391

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F2 · balance_after: Includes 292,490 shares underlying RSUs.

Read SEC document
October 28, 2024 Filed Oct 30, 2024 20:09 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,697 $6.06 $10,283.82
Disclosure

SEC source: 0000950170-24-118982 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 311,496

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,724 shares of restricted stock units ("RSUs") on October 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 292,490 shares underlying RSUs.

Read SEC document
September 27, 2024 Filed Oct 1, 2024 20:07 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 6,162 $7.46 $45,968.52
Disclosure

SEC source: 0000950170-24-110810 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 313,193

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $7.37 to $7.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 298,214 shares underlying RSUs.

Read SEC document
September 27, 2024 Filed Oct 1, 2024 20:07 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 295 $7.51 $2,215.45
Disclosure

SEC source: 0000950170-24-110810 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 319,355

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on September 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 298,214 shares underlying RSUs.

Read SEC document
July 29, 2024 Filed Jul 31, 2024 22:43 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 9,078 $8.51 $77,253.78
Disclosure

SEC source: 0000950170-24-088815 · ownership.xml · nonDerivative · entry 2

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 319,650

F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $8.22 to $8.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2 · balance_after: Includes 299,206 shares underlying RSUs.

Read SEC document
July 29, 2024 Filed Jul 31, 2024 22:43 UTC Relay Therapeutics, Inc. RLAY · Entity 4044 SaleCommon Stock 1,702 $8.85 $15,062.70
Disclosure

SEC source: 0000950170-24-088815 · ownership.xml · nonDerivative · entry 1

Catinazzo Thomas · CIK 0001818261 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 328,728

F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 5,723 shares of restricted stock units ("RSUs") on July 27, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

F2 · balance_after: Includes 299,206 shares underlying RSUs.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.